Close Menu

Luminex

The FDA gave the nod to Shenzhen Bioeasy Biotechnology for two lateral flow immunoassays that provide preliminary results in detecting marijuana in urine. 

The FDA clearance follows earlier US marketing approval for the firm's C. Difficile assay.

The investment bank adjusted its December 2020 price target for Luminex's stock to $21 and for Accelerate Diagnostics' stock to $16.

The firm's flow cytometry business contributed about $13.2 million, or 16 percent of the firm's consolidated revenue in the second quarter.

The firm said its assay is a real-time qPCR test for the direct detection of methicillin-resistant Staphylococcus aureus DNA in nasal swabs.

The test, called ColoPlex and being developed using the xMAP technology, is a blood test that uses multiplexed immunoassay technology and machine learning.

Get the latest news from Ivivoscribe, Todos Medical, Personalis, and Thermo Fisher Scientific for the week of 5/24/19.

The firm has three clinical trials in progress to validate the clinical utility of products it soon intends to submit for regulatory clearances to the FDA.

The firm said that it placed about 50 sample-to-answer molecular systems under contract during Q1, and it had about 625 active sample-to-answer product customers.

Pages